HuR degradation reveals dependencies in BRAF-driven cancers.

Abstract excerpt

Targeting RNA-binding proteins has been shown to be challenging due to the absence of druggable pockets. Recently, Lu et al. identified a molecular glue capable of degrading HuR and suppressing BRAF-mutant colorectal cancer. These findings offer a promising therapeutic pathway for the treatment of a subset of HuR-driven malignancies.

Topics

• Humans
• Proto-Oncogene Proteins B-raf
• Colorectal Neoplasms
• Mutation
• ELAV-Like Protein 1
• Gene Expression Regulation, Neoplastic
• Proteolysis